This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?
by Kinjel Shah
Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.
Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales
by Zacks Equity Research
Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
by Sundeep Ganoria
LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Novo Nordisk (NVO) closed at $52.05 in the latest trading session, marking a -1.59% move from the prior day.
Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings
by Kinjel Shah
Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
by Sundeep Ganoria
Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?
by Ahan Chakraborty
Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.
Strength Seen in Innoviva (INVA): Can Its 5.5% Jump Turn into More Strength?
by Zacks Equity Research
Innoviva (INVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Novo Nordisk (NVO) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Novo Nordisk (NVO) closed at $53.38 in the latest trading session, marking a -2.56% move from the prior day.
NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board
by Zacks Equity Research
Novo Nordisk stock slides as the Novo Nordisk Foundation pushes a sweeping board overhaul, signaling a new era in governance and strategic direction.
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients
by Zacks Equity Research
Novo Nordisk secures FDA approval for Rybelsus as the first oral GLP-1 therapy proven to cut major heart risks in adults with type II diabetes.
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
by Zacks Equity Research
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?
by Sundeep Ganoria
VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics
by Zacks Equity Research
Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Novo Nordisk (NVO) concluded the recent trading session at $56.09, signifying a -1.11% move from its prior day's close.
LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins
by Zacks Equity Research
Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its 2026 filing plans.
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
by Zacks Equity Research
Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
by Sundeep Ganoria
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
by Sundeep Ganoria
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
by Ahan Chakraborty
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $58.68, denoting a -1.56% move from the preceding trading day.
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
by Ahan Chakraborty
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.